Poster Session 16 – Wednesday, December 9, 2020: 8:00 AM CT
   
  Tumor Biology I
PS16-01 Intra-epithelial tumor immune landscapes are associated with clinical outcomes in early-stage triple-negative breast cancer
Carter JM, Chumsri S, Hillman DW, Zahrieh DM, Ma Y, Wang X, Kachergus JM, Boughey JC, Liu MC, Kalari KR, Villasboas JC, Ferre RAL, Couch FJ, Goetz MP, Thompson EA. Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL.
PS16-02 Moving in the fast lane: Test design and validation to produce up-to-date hereditary breast and gynecologic cancer tests
Angeloni TE, Bhattacharya A, Cheng LL, Chong HK, Conlan KM, Elzinga CD, Gerasimova A, Grover D, Grupe A, Hua M, Hodko D, Kazmierkiewicz K, Nakles RE, Nery CR, Owen R, Goos-Root DM, Rowland CM, Smolgovsky A, Weltmer EC, Zhang K, Lacbawan FL. Quest Diagnostics, San Juan Capistrano, CA; Athena Diagnostics, Marlborough, MA.
PS16-03 Clonal relatedness of LCIS with synchronous and asynchronous invasive disease
Sawyer E, Sborchia M, Megalios A, Shah V, Nowinski S, Vassart C, Grigoriadis A, Thompson A, Tomlinson I, Roylance R, Pinder S. KCL, London, United Kingdom; Baylor College of Medicine, Houston, TX; Edinburgh University, Edinburgh, United Kingdom; UCL, London, United Kingdom.
PS16-04 Estrogen receptor (ER) and NFkB activity determines cancer stem cell properties in ER positive breast cancer
Semina SE, Kastrati I, Cruz L, McCray T, Maienschein-Cline M, Alarid ET, Frasor J. Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL; Department of Cancer Biology, Loyola University Chicago, Chicago, IL; Department of Pathology, University of Illinois at Chicago, Chicago, IL; Core for Research Informatics, University of Illinois at Chicago, Chicago, IL; McArdle Laboratory for Cancer Research, Department of Oncology and Carbone Comprehensive Cancer Center, Madison, WI.
PS16-05 Identification of pathogenic RET alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer
Taylor ML, Mayro B, Drusbosky L, Anders C, Force J. Duke University, Durham, NC; Guardant Health, Redwood City, CA.
PS16-06 Identification of pathogenic FGFR1, FGFR2, and FGFR3 alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer
Taylor ML, Mayro B, Drusbosky L, Batchelder R, Marcom PK, Anders C, Force J. Duke University, Durham, NC; Guardant Health, Redwood City, CA.
PS16-07 Blocking H3K27me3 methyltransferase or demethylase activity impacts epithelial-mesenchymal plasticity, suppressing tumor growth and metastasis
Taube J, Das P, Johnson K, Landua J, Dobrolecki L, Lewis M. Baylor University, Waco, TX; Baylor College of Medicine, Houston, TX.
PS16-08 Germline mutation landscape in Chinese breast cancer patients
Wang N, Zhang J, Tan L, Liao H, Liu Y, Gui X, Niu J, Xie F, Zhang Y, Huang Y, Yu J, Li H. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China; Huidu (Shanghai) Medical Sciences, Ltd, Shanghai, China.
PS16-09 High infiltration of adipocytes is associated with inflammation, metastasis as well as favorable tumor immune microenvironment whereas low infiltration is associated with highly proliferative tumor in ER positive breast cancer patientsHigh infiltration of adipocytes is associated with inflammation, metastasis as well as favorable tumor immune microenvironment whereas low infiltration is associated with highly proliferative tumor in ER positive breast cancer patients
Tokumaru Y, Oshi M, Katsuta E, Matsuhashi N, Futamura M, Yoshida K, Takabe K. Roswell Park Comprehensive Cancer Institute, Buffalo, NY; Gifu University School of Medicine, Gifu, Japan.
PS16-10 Tao kinase 3 augment the resistance to microtubule-disrupting agents in breast cancer cells
Fang C-Y, Lai T-C, Hsiao M. Genomics Research Center, Academia Sinica, Taipei, Taiwan; Department of Pulmonary Medicine, WanFan Hospital, Taipei Medical University, Taipei, Taiwan.
PS16-11 Potential therapeutic effects of HDACi FK228 on TNBC using various models
Alzoubi M, Nguyen K, Hebert K, Matossian M, Burks H, Collins-Burow B, Burow M. Tulane University School of Medicine, New Orleans, LA.
PS16-12 Double heterozygous pathogenic variants prevalence in a cohort of hereditary breast cancer patients
Megid T, Achatz MI, Pontes Pisani J, Cartaxo M. Hospital Sirio Libanes, Sao Paulo, Brazil.
PS16-13 Mutarget.com - An online platform connecting mutation status to gene expression changes in solid tumours
Gyorffy B, Nagy A. TTK, Budapest, Hungary.
PS16-14 Eribulin and paclitaxel differentially affect exosome formation and release from triple negative breast cancer cells
Pederson PEJ, Liang H, Mooberry SL. University of Texas Health Science Center at San Antonio, San Antonio, TX.
PS16-15 The influence of mechanical and chemical insult on the integrity of vascular endothelial cells and associated impact on epithelial protein lost in neoplasm (EPLIN) and potential partner protein network
Zeng J, Sanders AJ, Martin TA, Jiang WG. Cardiff University School of Medicine, Cardiff, United Kingdom.
PS16-16 B-catenin-ccl2 axis regulates breast cancer stem cells via crosstalk between cancer cells and tumor-associated macrophages
Liu H, Liu B. Department of Genetics, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA.
PS16-17 Pml mediates tumor-associated macrophages to promote breast tumor progression
Long M, Kusi M, Liu R. Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; University of Texas Health Science Center at San Antonio, San Antonio, TX.
PS16-18 Inhibition of mTOR signaling by rapamycin abrogates mammary stem/progenitor cell activity in aged mice
Broome LE, Bouamar H, Nelson JF, Sun L-Z. University of Texas Health San Antonio, San Antonio, TX.
PS16-19 Hotspot p53 mutations correlate with increased expression of stem cell markers in triple-negative breast cancer
El-Dana F, Yuan B, Ly S, Anand V, Battula VL. MD Anderson Cancer Center, Houston, TX.
PS16-20 Targeting the RNA-binding protein HuR to overcome chemoresistance in triple-negative breast cancer
Wei L, Zhang Q, Gardashova G, Zhong C, Aubé J, Welch DR, Wu X, Xu L. The University of Kansas, Lawrence, KS.
PS16-21 Apc control of taxane resistance in breast cancer 
Prosperi J, Astarita E, Hoover C, Maloney S. IUSM-South Bend, South Bend, IN; University of Notre Dame, South Bend, IN.
PS16-22 Targeting resistance to current CDK4/6 therapies by RGT-419B, an inhibitor with optimized kinase activity spectrum
Xie Z, Han J, Hu Z, He H, Sun X, Zhang F, Lin J, Yao L, Wang X, Mei L, Liu Y, Zhu G, Chen X, Zhu X, Zhong W. Regor Pharmaceuticals Inc, San Diego, CA; Regor Therapeutics Inc, Shanghai, China; Regor Pharmaceuticals Inc, Boston, MA.
PS16-23 Elucidating the role of APC resulting in doxorubicin resistance in breast cancer
Prosperi J, Stefanski C. IUSM-South Bend, South Bend, IN; University of Notre Dame, South Bend, IN.
PS16-24 Mechanisms underlying obesity-induced enrichment of stem-like breast cancer cells
Mayberry S, Harlow B, Eichman E, Hsu C, and deGraffenried L. University of Texas at Austin, Austin, TX; Long School of Medicine, San Antonio, TX.
PS16-25 Comparison of the genetic mutations in sporadic and BRCA1 carrier breast cancer through targeted next generation sequencing
Barron CR, Hicks D, Wang X. University of Rochester Medical Center, Rochester, NY.
PS16-26 The prognostic role of MMP 9 in early breast cancer
Mego M, Cierna Z, Karaba M, Minarik G, Benca J, Sedlackova T, Mrvova I, Pindak D, Rejlekova K, Mardiak J, Kalavska K. Comenius University, Medical Faculty, Bratislava, Slovakia; National Cancer Institute, Bratislava, Slovakia; Comenius University, Faculty of Natural Sciences, Bratislava, Slovakia.
PS16-27 Small extracellular vesicle-mediated intercellular TGF-β1 transferring promotes adriamycin-resistant transmission in breast cancer cells
Xu Z, Tang J. The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
PS16-28 Runx3 regulates emt during development lapatinib resistance
Kim SH, Min A, Kim S, Park Y, Kim YJ, Im S-A. Seoul National University, Seoul, Republic of Korea.
PS16-29 Clinicopathological features of PALB2 and BRCA2 mutation carriers with breast cancer
Aranda-Gutierrez A, Ferrigno AS, García Marrufo JCA, Moncada-Madrazo M, Gomez-Picos A, Villarreal-Garza C, Aguilar D. Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico.
PS16-30 Pms1 gene: A new risk-mutation description?
Silva-Fernandes IJ, Picanço-Albuquerque CG, dos Santos Luciano MC, Tenazoa Wong DV, Barbosa Bezerra MJ, Bitencourt FS, Barbosa Oliveira FF, de Barros Silva PG, Sant´anna RO, Alves Lim MV. Haroldo Juaçaba Hospital, Fortaleza, Brazil.
PS16-31 SKT11 loss drives rapid cancer progression and fatal pulmonary tumor thrombotic microangiopathy (PTTM) in a breast cancer patient: A case report
Fujisawa F, Kunimasa K, Kano R, Kusama H, Nishio M, Matsui S, Yoshinami T, Kittaka N, Nagata S, Yagi T, Nakayama T, Tamaki Y, Imamura F. Osaka International Cancer Institute, Osaka, Japan.
PS16-32 Obg-like ATPase 1 enhances chemoresistance of breast cancer via activation of TGF-β/Smad axis cascades
Xiao G, Liu J, Miao X. Dalian University of Technology, Dalian, China.
PS16-33 Niclosamide reverses cisplatin resistance by inhibiting Bcl-2 and Stat3 in HER2-positive breast cancer
Liu N. Shanghai East Hospital, Tongji University School of Medicine,, Shanghai, China
PS16-34 Phenotype and prognosis of patients with breast cancer and pathogenic TP53 variants
Petry V. ICESP/ OncologiaDor, São Paulo, Brazil.
PS16-35 Microbiota and breast cancer in Mexican women
González Valdés AB, Bargallo Rocha JE, Medina Castro JM, Pérez Plasencia C, Millan Catalan O, Fernández Pérez E, Martinez AD, Cantú De león D. Instituto Nacional de Cancerología, Ciudad de Mexico, Mexico; Centro Oncologico Estatal Issemym, Toluca, Mexico.
   
  Tumor Cell and Molecular Biology: Drug Resistance
PS16-36 Paracrine signalling with stromal fibroblasts drives recovery of cancer cells after chemotherapy treatment
Maia A, Gu Z, Koch A, Berdiel-Acer M, Will R, Schlesner M, Wiemann S. DKFZ, Heidelberg, Germany; Eberhard-Karls-University Tübingen, Tübingen, Germany.